Compositions and Methods for Diagnosing, Treating and Monitoring Lyme Disease
OwnerChenggang Jin, Gottfried H. Kellermanninventors
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods for diagnosing, treating, and monitoring Lyme disease.
Claims97
A method for diagnosing Lyme disease in a subject, the method comprising:
- a. providing peripheral blood mononuclear cells (PBMCs) of the subject;
- b. incubating the PBMCs in a serum-free medium with one or more Lyme antigens;
- and
- c. measuring the level of one or more cytokines secreted by the PBMCs, wherein the level of one or more cytokines above a control level is indicative of Lyme disease in the subject.
A method for monitoring a treatment of Lyme disease in a subject, the method comprising:
- a. providing a first sample of peripheral blood mononuclear cells (PBMCs) obtained from the subject before the treatment;
- b. measuring a first level of one or more cytokines secreted by the first sample of PBMCs in response to stimulation by one or more Lyme antigens in serum-free medium;
- c. providing a second sample of PBMCs obtained from the subject during or after a treatment of Lyme disease;
- d. measuring a second level of one or more cytokines secreted by the second sample of PBMCs in response to stimulation by one or more Lyme antigens in serum-free medium;
- and
- e. comparing the first level with the second level.
A method of treating Lyme disease in a subject, the method comprising:
- a. providing peripheral blood mononuclear cells (PBMCs) of the subject;
- b. incubating the PBMCs in a serum-free medium with one or more Lyme antigens;
- c. measuring the level of one or more cytokines secreted by the PBMCs;
- d. if the level of the one or more cytokines is above a control level, administering to the subject a treatment comprising one or more antibiotics.
A composition comprising one or more Lyme antigen polypeptides selected from the group consisting of but not limited to a VlsE polypeptide or an antigenic fragment thereof, a NapA polypeptide or an antigenic fragment thereof, a DbpA polypeptide or an antigenic fragment thereof, a DbpB polypeptide or an antigenic fragment thereof, an OspC polypeptide or an antigenic fragment thereof, an OspA polypeptide or an antigenic fragment thereof, an OspB polypeptide or an antigenic fragment thereof, a P100 polypeptide or an antigenic fragment thereof, a P41 polypeptide or an antigenic fragment thereof, a P66 polypeptide or an antigenic fragment thereof, a BmpA polypeptide or an antigenic fragment thereof, a BmpB polypeptide or an antigenic fragment thereof, a BmpC polypeptide or an antigenic fragment thereof, a Bgp polypeptide or an antigenic fragment thereof, and a Fbp polypeptide or an antigenic fragment thereof.
Dependencies are inferred from the claim text.